PCVX Q4 2023 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$197M

Net Income

-$181M

EPS (Diluted)

$-1.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$129M

Free Cash Flow

-$186M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$167M

Stockholders' Equity

$1.2B

Cash & Equivalents

$397M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$197M	-$87M	-127.2%
Net Income	-$181M	-$78M	-131.6%